Fundz

Acer Therapeutics Inc. reported raising $3.13 Million in an initial SEC Form D filing, from an offering of $5.5 Million

PRIVATEApr 05, 2017$3.1M of $5.5M raised

Amount Raised

$3.13 Million

$3.13 Million sold, per SEC Form D (first sale Apr 5, 2017)

Round Type

Seed

NewtonBiotechnologyHealthcare

Who else raised in Healthcare and Biotechnology around the same time

Companies in the same sectors as Acer Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Northwest Biotherapeutics raised $52K (Pre-Seed) on May 17, 2017.
  • Cue Health raised $15M on May 16, 2017.
  • Elite Pharmaceuticals raised $800K (Seed) on May 10, 2017.
  • Treace raised $5.9M on May 10, 2017.
  • Infinite Arthroscopy Inc., Ltd raised an undisclosed amount on May 9, 2017.
  • Optimvia raised an undisclosed amount on May 8, 2017.

Who to call at Acer Therapeutics, and when

A new round usually means Acer Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Acer Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Acer Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Acer Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Acer Therapeutics

Location

One Gateway Center, Suite 356

Newton, Massachusetts, United States

About

Acer Therapeutics Inc. (Nasdaq: ACER) is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four programs: ACER-001 (a taste-masked, immediate-release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); emetine hydrochloride, a host-directed therapy against a variety of infectious diseases, initially for the treatment of patients with COVID-19; EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant for the treatment of induced Vasomotor Symptoms (iVMS). Each of Acer’s product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Acer's strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency. Acer has a strong company culture and is committed to creating and maintaining an environment that values individual rights, hard work, fosters creativity, and promotes success. The Company is growing and is fueled by the talent and expertise of our employees, driven by the commitment to treating patients with critical unmet medical needs.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Acer Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Acer Therapeutics's next move

See what Strategic adds

Acer Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.